Study on correlation of miR-181b and survival prognosis of patients with liver metastases from gastric cancer

doi:10.3877/cma.j.issn.2095-3232.2020.04.019

Abstract

Abstract:

Objective

To investigate the expression and clinical significance of miR-181b in patients with liver metastases from gastric cancer.

Methods

Clinical data of 164 patients with gastric cancer and 146 patients with liver metastases from gastric cancer who admitted in 909^th Hospital of PLA Joint Logistics Support Force from January 2006 to January 2013 and 160 healthy volunteers were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. In gastric cancer group, there were 94 male and 70 female patients, with a mean age of (49±10) years. In gastric cancer with liver metastases group, there were 83 male and 63 female patients, with a mean age of (50±9) years. In healthy volunteer group, there were 103 male and 57 female subjects, with a mean age of (49±10) years. The relative expression of miR-181b in the serum and gastric cancer tissues were quantified by qRT-PCR and the correlation between miR-181b and clinicopathological features as well as its prognosis value was analyzed. The miR-181b relative expression among three groups were compared by one-way analysis of variance and LSD-t test. Comparison between two groups were conducted with t test. Survival curves were plotted using Kaplan-Meier method and survival analysis was performed using Log-rank test.

Results

The relative expression of serum miR-181b in gastric cancer with liver metastases group was 2.3±0.9, which was significantly higher than 1.8±0.1 in gastric cancer group and 1.2±0.1 in healthy group (LSD-t=3.94, 82.33; P<0.05). The relative expression of miR-181 in gastric cancer tissues in liver metastases group was 2.6±0.2, significantly higher than 2.0±0.2 in gastric cancer group (t=31.87, P<0.05). The expression of miR-181b in gastric cancer tissues in liver metastases group was correlated with the diameter of liver metastasis, tumor differentiation, and invasion degree in stomach (t=-6.79, 8.99, -10.82; P<0.05). Survival analysis indicated that the overall survival in the group with high expression of miR-181b was significantly lower than that in the group with low expression of miR-181b (χ²=48.49, P<0.05).

Conclusions

miR-181b expression elevated significantly in the serum and cancerous tissue in patients with liver metastases from gastric cancer, and miR-181b was associated with the liver metastases from gastric cancer and its survival prognosis. It could be taken as a new indicator for the diagnosis and prognosis.

Key words: Stomach neoplasms, Neoplasm metastasis, MicroRNAs, miR-181b, Prognosis

Qingbo Yan, Pei Li, Huiming Lin. Study on correlation of miR-181b and survival prognosis of patients with liver metastases from gastric cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(04): 380-384.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2020.04.019

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2020/V09/I04/380

Figures/Tables 3

References 23

[1]	Ferlar J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J/CD]. Int J Cancer, 2015, 136(5):E359-386.
[2]	Nie Y, Wu K, Yu J, et al. A global burden of gastric cancer: the major impact of China[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(7): 651-661.
[3]	Yin J, Song JN, Bai ZG, et al. Gastric cancer mortality trends in China (2006-2013) reveal increasing mortality in young subjects[J]. Anticancer Res, 2017, 37(8):4671-4679.
[4]	Strong VE, D'Amico TA, Kleinberg L, et al. Impact of the 7th Edition AJCC staging classification on the NCCN clinical prac-tice guidelines in oncology for gastric and esophageal cancers[J]. J Natl Compr Canc Netw, 2013, 11(1):60-66.
[5]	Shinohara T, Maeda Y, Hamada T, et al. Survival benefit of surgical treatment for liver metastases from gastric cancer[J]. J Gastrointest Surg, 2015, 19(6):1043-1051.
[6]	Haider MT, Taipaleenmäki H. Targeting the metastatic bone microenvironment by microRNAs[J]. Front Endocrinol, 2018(9): 202.
[7]	Anfossi S, Fu X, Nagvekar R, et al. MicroRNAs, regulatory messengers inside and outside cancer cells[J]. Adv Exp Med Biol, 2018(1056):87-108.
[8]	Liu Y, Uzair-Ur-Rehman, Guo Y, et al. miR-181b functions asan oncomiR in colorectal cancer by targeting PDCD4[J]. Protein Cell, 2016, 7(10):722-734.
[9]	Chen Y, Li R, Pan M, et al. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor[J]. J Neurooncol, 2017, 133(3): 477-485.
[10]	Li D, Jian W, Wei C, et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer[J]. Int J Clin Exp Pathol, 2014, 7(11):7672-7680.
[11]	Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2[J]. Biochem Biophys Res Commun, 2014, 447(3):446-451.
[12]	中国研究型医院学会消化道肿瘤专业委员会，中国医师协会外科医师分会上消化道外科医师委员会，中国抗癌协会胃癌专业委员会，等．胃癌肝转移诊断与综合治疗中国专家共识（2019版）[J]. 中国实用外科杂志，2019, 39(5):405-411.
[13]	Petrelli F, Coinu A, Cabiddu M, et al. Hepatic resection for gastric cancer liver metastases: a systematic review and meta-analysis[J].J Surg Oncol, 2015, 111(8):1021-1027.
[14]	中国研究型医院学会消化道肿瘤专业委员会，中国医师协会外科医师分会多学科综合治疗专业委员会．胃癌多学科综合治疗协作组诊疗模式专家共识[J]．中国实用外科杂志，2017, 37(1):37-38.
[15]	陈德兴，张洪伟．胃癌肝转移治疗现状[J]．中国实用外科杂志，2019, 39(4):382-384, 390.
[16]	Li Z, Fan B, Shan F, et al. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis:a prospectively comparative study[J]. World J Surg Onc, 2015(13): 212.
[17]	Ishida M, Shimabukuro M, Yagi S, et al. MicroRNA-378 regulates adiponectin expression in adipose tissue: a new plausible mechanism[J]. PLoS One, 2014, 9(11):e111537.
[18]	Yuan HL, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer[J]. Onco Targets Ther, 2018(11):3891-3900.
[19]	Wang X, Gocek E, Liu CG, et al. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3[J]. Cell Cycle, 2009, 8(5):736-741.
[20]	Ouyang YB, Lu Y, Yue S, et al. miR-181 targets multiple Bcl-2 family members and nfluences apoptosis and mitochondrial function in astrocytes[J]. Mitochondrion, 2012, 12(2):213-219.
[21]	Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3[J]. Oncogene, 2010, 29(12):1787-1797.
[22]	Yang CC, Hung PS, Wang PW, et al. miR-181 as a putative biomarker for lymph-node metastasis of oral quamous cell carcinoma[J]. Oral Pathol Med, 2011, 40(5):397-404.
[23]	Zheng J, Wu C, Xu Z, et al. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway[J]. Mol Cell Biochem, 2015, 398(1/2):1-9.

组别	例数	年龄（岁，±s）	性别（例，男/女）	吸烟（例）	HP感染（例）
胃癌组	164	49±10	94/70	63	74
胃癌肝转移组	146	50±9	83/63	41	66
健康组	160	49±10	103/57	52	62
统计值	?	H=0.67	χ²=2.32	χ²=3.76	χ²=1.77
P值	?	0.540	0.312	0.152	0.413

组别	例数	年龄（岁，±s）	性别（例，男/女）	吸烟（例）	HP感染（例）
胃癌组	164	49±10	94/70	63	74
胃癌肝转移组	146	50±9	83/63	41	66
健康组	160	49±10	103/57	52	62
统计值	?	H=0.67	χ²=2.32	χ²=3.76	χ²=1.77
P值	?	0.540	0.312	0.152	0.413

因素		例数	miR-181b表达量	t值	P值
性别		?	?	-1.21	0.226
?	男	83	2.6±0.1	?	?
?	女	63	2.6±0.2	?	?
年龄		?	?	-0.08	0.936
?	<55岁	100	2.6±1.4	?	?
?	≥55岁	46	2.6±1.5	?	?
肝转移肿瘤直径		?	?	-6.79	<0.010
?	<2 cm	65	2.5±0.2	?	?
?	≥2 cm	81	2.6±0.1	?	?
肿瘤分化程度		?	?	8.99	<0.010
?	低、未分化	71	2.7±0.9	?	?
?	中、高分化	75	2.5±0.1	?	?
胃内浸润深度		?	?	-10.82	<0.010
?	T1～T2	79	2.5±0.1	?	?
?	T3～T4	67	2.7±0.7	?	?

因素		例数	miR-181b表达量	t值	P值
性别		?	?	-1.21	0.226
?	男	83	2.6±0.1	?	?
?	女	63	2.6±0.2	?	?
年龄		?	?	-0.08	0.936
?	<55岁	100	2.6±1.4	?	?
?	≥55岁	46	2.6±1.5	?	?
肝转移肿瘤直径		?	?	-6.79	<0.010
?	<2 cm	65	2.5±0.2	?	?
?	≥2 cm	81	2.6±0.1	?	?
肿瘤分化程度		?	?	8.99	<0.010
?	低、未分化	71	2.7±0.9	?	?
?	中、高分化	75	2.5±0.1	?	?
胃内浸润深度		?	?	-10.82	<0.010
?	T1～T2	79	2.5±0.1	?	?
?	T3～T4	67	2.7±0.7	?	?

Please choose a citation manager

Content to export